Business
Jaguar Health Subsidiary Napo Pharmaceuticals Completes Filing of Investigational New Drug Application for Crofelemer (Mytesi) for Symptomatic Relief of Cancer Therapy‑Related Diarrhea
A significant proportion of patients undergoing cancer therapy experience diarrheaSAN FRANCISCO, CA / ACCESSWIRE / July 6, 2020 / Jaguar Health, Inc.
About this update from Jaguar Health, Inc.
[{"type":"text","content":"A significant proportion of patients undergoing cancer therapy experience diarrheaSAN FRANCISCO, CA / ACCESSWIRE / July 6, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) (\"Jaguar\" or the \"Company\") announced today that the Company's wholly owned subsidiary Napo Pharmaceuticals, Inc. (\"Napo\") has completed the filing of the investigational new drug application (IND) with the U.S. Food and Drug Administration (FDA) for crofelemer (Mytesi®) for the planned indication of prophylaxis and symptomatic relief of diarrhea in adult patients with solid tumors receiving targeted therapy with or without standard chemotherapy (\"cancer therapy‑related diarrhea\" (CTD)).A significant proportion of patients undergoing cancer therapy experience diarrhea. Novel \"targeted cancer therapy\" agents, such as epidermal growth factor receptor (EGFR) antibodies and tyrosine kinase inhibitors (TKIs), with or without cycle chemotherapy agents, may activate intestinal chloride ion channel-mediated secretory pathways leading to increased electrolyte and fluid content in the gut lumen, which results in passage of loose/watery stools, i.e. secretory diarrhea.\"Many cancer patients on targeted therapy require drug holidays or dose reductions in their therapy due to diarrhea,\" Lisa Conte, Jaguar's president and CEO, stated. \"Reducing frequency of watery stools will provide symptomatic relief of diarrhea and should allow better adherence to the therapeutic dosing of any targeted therapies, potentially leading to better clinical outcomes. We have learned from business development discussions with cancer drug manufacturers that adoption and continued use of targeted cancer therapies is directly related to the ability of patients to tolerate use of the therapies - highlighting the importance of supportive care drugs like Mytesi to help manage cancer treatment-related diarrhea in this patient population.\"Mytesi, a novel non-opiate, plant-based, chloride ion channel modulating antidiarrheal medicine, is currently commercialized for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy. Crofelemer, the active ingredient in Mytesi, comes from the Croton lechleri tree, which is responsibly and sustainably harvested in South America.About Jaguar Health, Inc.Jaguar Health, Inc. is a commercial stage pharmaceuticals c...